"I really wanna see the mass driver on the moon that is shooting AI satellites into deep space. Just going like 'shoom, shoom,' just one after the other." Reading time 5 minutes At the risk of stating ...

The Food and Drug Administration has declined to approve Regenxbio's gene therapy, RGX-121, for the treatment of Hunter syndrome, a rare and fatal neurodegenerative disease. The clinical-stage ...

Acadia Pharmaceuticals said that drug regulators in Europe are leaning toward rejecting its application for a neurodevelopmental disorder treatment. The company said Monday it was informed by a ...

MILAN--(BUSINESS WIRE)--With the decision by the U.S. Food and Drug Administration and the European Commission to grant market authorization for Waskyra™, a gene therapy to treat Wiskott-Aldrich ...

Encoded Therapeutics, Inc. ("Encoded"), a clinical-stage biotechnology company developing precision genetic medicines for severe neurological disorders, today announced that the U.S. Food and Drug ...

Fatigue can stem from a variety of illnesses and life stressors, but when that exhaustion lasts for months — often following an infection — it may indicate a condition called chronic fatigue syndrome.

BAY 3401016 is an investigational monoclonal antibody with potential to block a protein called Semaphorin 3A (Sema3A), which is thought to be involved in the progression of kidney damage in Alport ...

Biologics, including GLP-1 analogs and PCSK9 inhibitors, are advancing treatment options for metabolic syndrome components like type 2 diabetes and dyslipidemia. GLP-1 receptor agonists improve ...

A generic form of teduglutide, Teduglutide Viatris (Viatris Limited), that cuts parenteral nutrition needs in patients with short-bowel syndrome (SBS) has received a positive opinion from the European ...

Delgocitinib has emerged as a promising treatment for CHE, addressing unmet needs and enhancing understanding of this complex condition, notes Raj Chovatiya, MD, PhD, MSCI. Chronic hand eczema (CHE) ...